GSK Bio
NEWS
Sir Andrew Witty, the former head of GlaxoSmithKline, current president of UnitedHealth Group and chief executive officer of Optum, is temporarily stepping away from his duties to co-lead a World Health Organization effort to combat COVID-19.
It’s likely that more companies and universities will add additional assets as time goes on.
The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.
Following close on the heels of its vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
Companies strengthen their leadership teams and executive boards with this week’s Movers & Shakers.
Priority Review for BLA submission was granted by U.S. FDA for tafasitamab in combination with lenalidomide for relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) based on positive primary analysis data of L-MIND and Re-MIND studies
Zai Lab Limited announced the China National Medical Products Administration has accepted its supplemental New Drug Application for ZEJULA® as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
Companies strengthen their leadership teams and executive boards with this week’s Movers & Shakers.
JOBS
IN THE PRESS